Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $71.27 USD
Change Today -0.37 / -0.52%
Volume 680.1K
DXCM On Other Exchanges
DXCM is not on other exchanges.
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

dexcom inc (DXCM) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/28/15 - $71.80
52 Week Low
06/3/14 - $32.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DEXCOM INC (DXCM)

dexcom inc (DXCM) Related Businessweek News

No Related Businessweek News Found

dexcom inc (DXCM) Details

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes DexCom G4 system, a continuous glucose monitoring system; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring. Its in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. The company also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. DexCom, Inc. markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. The company was founded in 1999 and is headquartered in San Diego, California.

838 Employees
Last Reported Date: 02/25/15
Founded in 1999

dexcom inc (DXCM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $325.0K
Executive Chairman
Total Annual Compensation: $420.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $248.9K
Chief Technical Officer and Executive Vice Pr...
Total Annual Compensation: $296.4K
Executive Vice President of Strategy & Corpor...
Total Annual Compensation: $296.4K
Compensation as of Fiscal Year 2014.

dexcom inc (DXCM) Key Developments

Dexcom Unveils New Continuous Glucose Monitoring System

Nordic Semiconductor ASA has announced that Dexcom has unveiled its G4 Platinum continuous glucose monitoring, or CGM, system. Nordic Semiconductor announced that Dexcom, is now shipping what Dexcom claims is the world's first commercially-available continuous diabetic monitoring solution with continuous (24x7) remote monitoring by adding Bluetooth Smart (formerly known as Bluetooth low energy) wireless connectivity to Dexcom's existing G4 Platinum CGM (Continuous Glucose Monitoring) handheld using the Nordic Blue nRF8001 Single-Chip-Connectivity solution. This enables the blood glucose monitor to securely transmit glucose information to a free Dexcom app running on any iOS (and shortly Android) Bluetooth Smart Ready smartphone. The Dexcom G4 Platinum CGM System with Share allows blood glucose readings to be measured at a frequency of up to once every five minutes and shared with the mobile devices of up to five designated 'follower' recipients who can then remotely monitor a diabetic's glucose information and receive alert notifications from almost anywhere in the world with cellular network coverage.

DexCom, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Revenue Guidance for the Year 2015

DexCom, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $72.8 million compared to $47.1 million a year ago. Operating loss was $12.7 million compared to $12.3 million a year ago. Net loss was $12.9 million or $0.17 per diluted share compared to $12.5 million or $0.17 per basic and diluted share a year ago. As adjusted, net income on a cash basis was $10 million, higher than it was a year ago. For the fiscal year 2015, the company expects revenue of $340 million to $360 million.

DexCom, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 02:20 PM

DexCom, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 02:20 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Kevin R. Sayer, Chief Executive Officer, President and Director, Steven R. Pacelli, Executive Vice President of Strategy & Corporate Development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DXCM:US $71.27 USD -0.37

DXCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merge Healthcare Inc $4.62 USD -0.07
NeuStar Inc $27.37 USD +0.38
Radview Software Ltd $0.0017 USD 0.00
Smiths Group PLC 1,201 GBp -18.00
Tandem Diabetes Care Inc $11.91 USD +0.14
View Industry Companies

Industry Analysis


Industry Average

Valuation DXCM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.6x
Price/Book 38.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEXCOM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at